European startup Enough has announced that it has secured 40 million euros in funding to double its mycoprotein production capacity. Enough is Europe’s leading producer of mycoprotein, a plant-based alternative to meat that has proven to be both more sustainable and environmentally friendly.
The funds secured from investors such as Acre Venture Partners, JM Finn & Co and Rabo Corporate Investments will go towards building a second mycoprotein production facility in East-Flanders, Belgium. This facility will double Enough’s production capacity and make it the largest mycoprotein producer in Europe.
Enough CEO Erik de Boer expressed his enthusiasm: “At Enough we are on a mission to make sustainably produced plant-based food products available to everyone, everywhere. With this extra capacity we are taking a major step towards providing plant-based food solutions to our customers around Europe.”
The new production facility will allow Enough to become a major player in the European plant-based food market, and the company’s VP of Innovation and Product Development, Dr. Sascha Karusseit, sees this as an opportunity for the company to grow even further: “With the new production facility, we are in an excellent position to quickly respond to customer demand and heavier commercial considerations such as private labels as well as our own branded products.”
The new production facility is set to be up and running by 2021 and the additional capacity will allow Enough to increase their production of not only mycoprotein, but also plant-based pasta, snacks, and ice cream.
With investors such as Acre Venture Partners, JM Finn & Co and Rabo Corporate Investments throwing their support behind the project, the future looks bright for Enough and its efforts to expand the production of sustainable plant-based food solutions. Enough’s CEO Erik de Boer is confident in the project: “This important milestone marks the start of our next phase of growth and paves the way for further expansion of our production capabilities in Europe.”
Hey Subscribe to our newsletter for more articles like this directly to your email.